Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy
暂无分享,去创建一个
M. Graefen | C. Rödel | M. Wenzel | C. Humke | P. Mandel | N. Tselis | D. Tilki | F. Koll | B. Hoeh | F. Chun | C. C. Garcia | Charlotte Jorias
[1] T. Steuber,et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. , 2023, European urology focus.
[2] B. Tombal,et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. D'Amico,et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] T. Steuber,et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. , 2022, European urology focus.
[5] J. Carles,et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.
[6] M. Graefen,et al. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. , 2021, Urologic oncology.
[7] F. Saad,et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis , 2021, Prostate Cancer and Prostatic Diseases.
[8] F. Saad,et al. Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy , 2021, The Prostate.
[9] M. Scorsetti,et al. Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance , 2021, Medical Oncology.
[10] H. Heinzer,et al. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies , 2021, Frontiers in Oncology.
[11] F. Saad,et al. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. , 2021, European urology focus.
[12] L. Budäus,et al. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study , 2021, The Journal of urology.
[13] M. Graefen,et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer , 2021, Prostate international.
[14] M. Zelefsky,et al. Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer , 2020, Advances in radiation oncology.
[15] K. Pienta,et al. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer , 2020, Medical Oncology.
[16] Ash A. Alizadeh,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.
[17] C. Fiorino,et al. Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. , 2020, The British journal of radiology.
[18] P. Boutros,et al. What Is Oligometastatic Prostate Cancer? , 2019, European urology focus.
[19] R. Weichselbaum,et al. Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.
[20] N. Lawrentschuk,et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.
[21] M. Scorsetti,et al. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer , 2018, Cancer medicine.
[22] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Laudone,et al. A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. , 2017, Urology.
[24] R. Miralbell,et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[25] M. Roach,et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.
[26] C. Pipper,et al. [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.
[27] K. Pienta,et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.
[28] F. Trippa,et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience , 2016, World Journal of Urology.